Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Enable Injections , developer of ... it easy and nearly painless for patients to self-inject ... has been named winner of the ,Buzz of BIO ... biotech sector.    Enable is one of only ... number of votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... Sept. 23, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... to its Scientific Advisory Board.  The new members are ... , PhD. Dr. Acker is a Senior ...
(Date:9/23/2014)... LONDON , September 23, 2014 ... pharmaceutical assets, announces the appointment of Jarrod ... role, Mr Longcor is responsible for structuring, negotiating ... financial investments, as well as providing management and ... member of the Executive leadership team. ...
Breaking Medicine Technology:Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... May 26, 2011 Rigel Pharmaceuticals, Inc. ... of its previously announced underwritten public offering of 16,300,000 ... of $8.00 per share to the public. The gross ... be approximately $130,400,000, before deducting underwriting discounts and commissions, ...
... Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP ) ... amount of senior unsecured notes. The notes will be unsecured, ... certain of the Company,s subsidiaries.   Endo intends ... cash on hand and borrowings under its new credit facility, ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes 2
(Date:9/23/2014)... 2014 Hope For The Warriors® is ... to be hosted in Boston, Massachusetts on Sunday, November ... This signature event honors the courage of our wounded ... fallen. Proceeds from the evening will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
(Date:9/23/2014)... Ithaca, New York (PRWEB) September 23, 2014 ... vulvodynia, interstitial cystitis, pudendal neuralgia, and other chronic pelvic or ... to lasting relief. , According to the Gallup poll, 1 ... suffer from chronic pelvic pain. Many of those women ... with their healthcare providers. The type of pain varies ...
(Date:9/23/2014)... 2014 People across Minnesota acknowledge that ... choices, but barriers are more prominent in the state’s ... Center for Prevention at Blue Cross and Blue Shield ... to healthy, affordable food and a lack of places ... About 60 percent of rural Minnesotans who responded to ...
(Date:9/23/2014)... 23, 2014). Researchers from the University of ... Krischek, investigated gene expression in normal vestibular nerves ... made: 1) there is negligible difference between VSs ... neurofibromatosis Type 2 (NF2), a genetic disorder; and ... tumors may be an excellent therapeutic target. Detailed ...
(Date:9/23/2014)... "Bee Towers” was featured on NewsWatch as part of its ... gadgets and services available to consumers. Mallory Sofastaii, a host ... and shared with viewers how it can hold tablets ... in the United States continue to climb. According to ... , For consumers who own a tablet but want ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:Mind Body Expert Launches Pelvic Pain Relief Program 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 3Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 4Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 5Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 3Health News:“Bee Towers”, a Floor Standing Tablet Holder by XAR Motion, was Featured on NewsWatch, a National Television Show, This Month 2
... EUR10.8 Million in ... ... (Nasdaq: CHDX ), an independent American provider of international,healthcare services ... that it has signed two contracts for the,supply of EUR10.8 million ...
... Because of the demographic changes, there will be a ... in 2004, the medical costs for the care of ... In their original article in the current edition of ... 105[26]: 467󈞵), the neurologist Tobias Neumann-Haefelin of the Johann ...
... in #1 respiratory hospital ranking, DENVER, July ... traditional boundaries of respiratory medicine into,exciting new areas ... Center will become National Jewish Health, effective immediately., ... put, this isn,t just about a name change. ...
... series of online NHS Health Guides,for people with long-term ... NHS Choices http://www.nhs.uk , These online guides ... diagnosis, and through to how to live and self ... be rolling out more,guides from the 60 most common ...
... BROOK, Ill. C JULY 11, 2008 -- A study ... of Radiology,s (ACR) CT colonography guidelines recommending that polyps ≤ ... applying them to an endoscopic database that collected information about ... also recommend that patients with one or two polyps 6 ...
... Placing 15 of its 16 Ranked Specialties Ahead of All ... Clinic Specialties Rated Among Nation,s Top Ten, ... Clinic,s cardiac care has been ranked No. 1 in the nation,according ... The survey recognizes Cleveland Clinic as one of the nation,s ...
Cached Medicine News:Health News:Chindex International, Inc. Announces CDC Contract Signing 2Health News:Chindex International, Inc. Announces CDC Contract Signing 3Health News:Chindex International, Inc. Announces CDC Contract Signing 4Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 2Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 3Health News:Online NHS Health Guides for Long-Term Conditions Released on NHS Choices 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 3Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 4Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 2Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 3
... ENA Multiparameter Kit is designed ... six of the most common ... unique quality control system. The ... well in each strip gives ...
Inquire...
Microalbumin Linearity Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
Medicine Products: